Safety and Immunogenicity of a Vaccine Dendritic Cell-based Pulsed With Autologous Heat-inactivated in HIV-1 Infected Patients

Inclusion criteria

• Patient > 18 years of age;
• Voluntarily sign informed consent;
• Men or women with a negative pregnancy test before inclusion in the study;
• HIV infection tested (with positive antibodies to HIV-1 and a detectable viral load);
• Patient must be on stable treatment with cART at least 1 year
• The average of all measurements of CD4 during the year before starting cART should be equal or greater than 350 cells / mm3
• The number of CD4 + at enrollment must be equal or greater than 450 cells / mm3;
• Plasma HIV viral load undetectable at least 6 months before the inclusion in the study, at least two determinations (occasional blips above the undetectable level are allowed).

Exclusion criteria

• Treatment with suboptimal regimen (less than 3 antiretroviral drugs) before starting cART;
• History of C CDC events;
• Interruption of cART during the inclusion in the study;
• Pregnancy woman or becoming pregnant in the next months;
• Active opportunistic infections, or any active infection or cancer within 30 days prior to the screening visit;
• Therapy with immunomodulatory agents, including cytokines (eg IL-2) and gamma globulins or chemotherapy within 90 days prior to the screening visit;
• Use of anticoagulant medication;
• Use of any investigational drug within 90 days prior to study entry;
• Virological failure prior to antiretroviral treatment and / or mutations that confer resistance to antiretroviral drugs;
• Uncontrolled psychiatric disorder;
• Platelet count <80,000 / mm3;
• Values ??of hemoglobin <12g / dL;
• Patients with active uncontrolled autoimmune diseases;
• Using contraindicated drugs in accordance with the Summary of Product Specifications of pegylated interferon;
• Childbearing, or potential childbearing not using highly effective contraception;
• Any other problem that according to the investigator could interfere with the evaluation of the objectives.
• Any contraindication for the use of interferon peg in accordance with the Summary of Product Characteristics.